Novartis Forecast, price target & analysts
Novartis Target price 2025 - Analyst rating & recommendation
Novartis Classifications & Recommendation:
Novartis Price Target
| Target Price | CHF105.06 |
| Price | CHF94.06 |
| Potential | 11.69% |
| Number of Estimates | 23 |
| 23 Analysts have issued a price target Novartis 2026 . The average Novartis target price is CHF105.06. This is 11.69% higher than the current stock price. The highest price target is CHF124.95 32.84% , the lowest is CHF78.78 16.24% . | |
| A rating was issued by 31 analysts: 13 Analysts recommend Novartis to buy, 14 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Novartis stock has an average upside potential 2026 of 11.69% . Most analysts recommend the Novartis stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2032
24 Analysts have issued a sales forecast Novartis 2025 . The average Novartis sales estimate is CHF45.6b . This is 2.76% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF49.2b 10.98% , the lowest is CHF41.8b 5.80% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF41.8b | 10.85% |
|---|---|---|
| 2025 | CHF45.6b | 8.96% |
| 2026 | CHF46.6b | 2.34% |
| 2027 | CHF47.9b | 2.74% |
| 2028 | CHF47.9b | 0.06% |
| 2029 | CHF49.2b | 2.57% |
| 2030 | CHF49.9b | 1.58% |
| 2031 | CHF48.4b | 2.99% |
| 2032 | CHF44.4b | 8.28% |
20 Analysts have issued an Novartis EBITDA forecast 2025. The average Novartis EBITDA estimate is CHF18.3b . This is 21.78% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF20.0b 33.03% , the lowest is CHF13.8b 8.17% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF13.4b | 26.63% |
|---|---|---|
| 2025 | CHF18.3b | 37.09% |
| 2026 | CHF18.7b | 2.15% |
| 2027 | CHF19.4b | 3.55% |
| 2028 | CHF21.2b | 9.37% |
| 2029 | CHF22.3b | 5.04% |
| 2030 | CHF21.8b | 1.91% |
| 2031 | CHF18.3b | 15.97% |
| 2032 | CHF16.1b | 12.15% |
EBITDA Margin
| 2024 | 31.96% | 14.24% |
|---|---|---|
| 2025 | 40.21% | 25.82% |
| 2026 | 40.14% | 0.17% |
| 2027 | 40.45% | 0.77% |
| 2028 | 44.22% | 9.32% |
| 2029 | 45.28% | 2.40% |
| 2030 | 43.73% | 3.42% |
| 2031 | 37.88% | 13.38% |
| 2032 | 36.28% | 4.22% |
26 Novartis Analysts have issued a net profit forecast 2025. The average Novartis net profit estimate is CHF13.6b . This is 23.26% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF15.9b 43.72% , the lowest is CHF11.4b 2.96% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF9.7b | 19.59% |
|---|---|---|
| 2025 | CHF13.6b | 40.94% |
| 2026 | CHF14.2b | 4.20% |
| 2027 | CHF15.2b | 7.53% |
| 2028 | CHF16.1b | 5.57% |
| 2029 | CHF16.8b | 4.14% |
| 2030 | CHF16.9b | 0.76% |
| 2031 | CHF15.0b | 11.25% |
| 2032 | CHF13.0b | 13.42% |
Net Margin
| 2024 | 23.09% | 27.46% |
|---|---|---|
| 2025 | 29.86% | 29.34% |
| 2026 | 30.41% | 1.84% |
| 2027 | 31.83% | 4.67% |
| 2028 | 33.58% | 5.50% |
| 2029 | 34.10% | 1.55% |
| 2030 | 33.82% | 0.82% |
| 2031 | 30.94% | 8.52% |
| 2032 | 29.21% | 5.59% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
26 Analysts have issued a Novartis forecast for earnings per share. The average Novartis EPS is CHF7.03 . This is 24.87% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF8.19 45.47% , the lowest is CHF5.87 4.26% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF4.74 | 17.28% |
|---|---|---|
| 2025 | CHF7.03 | 48.31% |
| 2026 | CHF7.32 | 4.13% |
| 2027 | CHF7.87 | 7.51% |
| 2028 | CHF8.31 | 5.59% |
| 2029 | CHF8.66 | 4.21% |
| 2030 | CHF8.72 | 0.69% |
| 2031 | CHF7.74 | 11.24% |
| 2032 | CHF6.70 | 13.44% |
P/E ratio
| Current | 16.71 | 12.92% |
|---|---|---|
| 2025 | 13.38 | 19.91% |
| 2026 | 12.84 | 4.04% |
| 2027 | 11.94 | 7.01% |
| 2028 | 11.31 | 5.28% |
| 2029 | 10.86 | 3.98% |
| 2030 | 10.78 | 0.74% |
| 2031 | 12.15 | 12.71% |
| 2032 | 14.03 | 15.47% |
Based on analysts' sales estimates for 2025, the Novartis stock is valued at an EV/Sales of 4.34 and an P/S ratio of 3.89 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.46 | 21.20% |
|---|---|---|
| 2025 | 4.34 | 2.64% |
| 2026 | 4.24 | 2.28% |
| 2027 | 4.13 | 2.67% |
| 2028 | 4.13 | 0.06% |
| 2029 | 4.02 | 2.50% |
| 2030 | 3.96 | 1.55% |
| 2031 | 4.08 | 3.08% |
| 2032 | 4.45 | 9.03% |
P/S ratio
| Current | 3.99 | 23.68% |
|---|---|---|
| 2025 | 3.89 | 2.68% |
| 2026 | 3.80 | 2.28% |
| 2027 | 3.70 | 2.67% |
| 2028 | 3.70 | 0.05% |
| 2029 | 3.60 | 2.50% |
| 2030 | 3.55 | 1.55% |
| 2031 | 3.66 | 3.08% |
| 2032 | 3.99 | 9.03% |
Current Novartis Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JEFFERIES |
Hold
➜
Hold
|
Unchanged | Jul 16 2025 |
| TD COWEN |
Hold
➜
Hold
|
Unchanged | Jul 16 2025 |
| GUGGENHEIM SECURITIES LLC |
Neutral
➜
Neutral
|
Unchanged | Jul 16 2025 |
| ARGUS RESEARCH CORPORATION |
Hold
➜
Hold
|
Unchanged | Jul 10 2025 |
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Jul 08 2025 |
| ROTHSCHILD & CO REDBURN |
Sell
➜
Sell
|
Unchanged | Jul 03 2025 |
| DAY BY DAY |
Buy
➜
Hold
|
Downgrade | Jun 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Jul 16 2025 |
|
Unchanged
TD COWEN:
Hold
➜
Hold
|
Jul 16 2025 |
|
Unchanged
GUGGENHEIM SECURITIES LLC:
Neutral
➜
Neutral
|
Jul 16 2025 |
|
Unchanged
ARGUS RESEARCH CORPORATION:
Hold
➜
Hold
|
Jul 10 2025 |
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Jul 08 2025 |
|
Unchanged
ROTHSCHILD & CO REDBURN:
Sell
➜
Sell
|
Jul 03 2025 |
|
Downgrade
DAY BY DAY:
Buy
➜
Hold
|
Jun 08 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
